[N+:1]([C:4]1[C:13]([Cl:14])=[C:12]([Cl:15])[CH:11]=[C:10]2[C:5]=1[N:6]=[C:7](Cl)[C:8]([Cl:16])=[N:9]2)([O-:3])=[O:2].[CH3:18][C:19]([CH3:22])([O-:21])[CH3:20].[K+].C1(C)C=CC=CC=1.O>C(O)(C)(C)C>[C:19]([O:21][C:7]1[C:8]([Cl:16])=[N:9][C:10]2[C:5](=[C:4]([N+:1]([O-:3])=[O:2])[C:13]([Cl:14])=[C:12]([Cl:15])[CH:11]=2)[N:6]=1)([CH3:22])([CH3:20])[CH3:18]To 5-nitro-2,3,6,7-tetrachloroquinoxaline 1608 mg obtained in Example 7(1), was added dropwise a solution of potassium tert-butoxide 644 mg in tert-butanol (15 mL) at −5 to 0° C. The reaction mixture was stirred at 0° C. for 30 min, and toluene 50 mL, 0.1 M sodium dihydrogen phosphate 5 mL, and water were added thereto with shaking. The organic layer was separated, washed with water and saturated saline, and dried over MgSO4. After evaporation, the residue was subjected to column chromato (silica gel/toluene) and crystallized from acetone, to give the title compound (colorless crystal) 1092 mg.
読み込み中…
